Genomic-scale prioritization of drug targets: the TDR Targets database
暂无分享,去创建一个
John P. Overington | G. V. Paolini | Santiago J. Carmona | Gregory J. Crowther | Ian M. Carruthers | A. Sali | B. Al-Lazikani | A. Hopkins | M. Aslett | M. Berriman | A. Pain | D. Roos | S. Ralph | Fernán Agüero | F. Buckner | R. Campbell | S. Carmona | A. Chan | Feng Chen | M. Doyle | C. Hertz-Fowler | Gregg McAllister | S. Nwaka | U. Pieper | Aaron Riechers | Dhanasekaran Shanmugam | Takashi Suzuki | W. V. Voorhis | C. Verlinde
[1] S. Beverley,et al. Development of a safe live Leishmania vaccine line by gene replacement. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[2] Ken Blanchard,et al. Mission Possible , 1999 .
[3] Ronald W. Davis,et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.
[4] J. Varghese,et al. Development of neuraminidase inhibitors as anti‐influenza virus drugs , 1999 .
[5] Peter M Woollard,et al. Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. , 2002, Microbiology.
[6] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[7] Y. Dong,et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi , 2003, Nature.
[8] Karl W. Broman,et al. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. W. Campbell,et al. Experimental Determination and System Level Analysis of Essential Genes in Escherichia coli MG1655 , 2003, Journal of bacteriology.
[10] E. Rubin,et al. Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.
[11] E. Oldfield,et al. Farnesyl Pyrophosphate Synthase Is an Essential Enzyme in Trypanosoma brucei , 2003, The Journal of Biological Chemistry.
[12] D. Roos,et al. Purine Salvage Pathways in the Apicomplexan Parasite Toxoplasma gondii* , 2004, Journal of Biological Chemistry.
[13] Marc A. Martí-Renom,et al. MODBASE: a database of annotated comparative protein structure models and associated resources , 2005, Nucleic Acids Res..
[14] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[15] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[16] Feng Chen,et al. OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups , 2005, Nucleic Acids Res..
[17] Samiul Hasan,et al. Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis , 2006, PLoS Comput. Biol..
[18] Solomon Nwaka,et al. Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.
[19] O. Heby,et al. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas’ disease, and leishmaniasis , 2007, Amino Acids.
[20] Fangfang Xia,et al. The National Microbial Pathogen Database Resource (NMPDR): a genomics platform based on subsystem annotation , 2006, Nucleic Acids Res..
[21] P. Gilson,et al. Molecular genetic tools in Toxoplasma and Plasmodium: achievements and future needs. , 2007, Current opinion in microbiology.
[22] A. Hopkins,et al. Mission possible , 2002, Nature.
[23] J. Vermunt,et al. Assessing Performance of Orthology Detection Strategies Applied to Eukaryotic Genomes , 2007, PloS one.
[24] Jonathan E. Allen,et al. Draft Genome of the Filarial Nematode Parasite Brugia malayi , 2007, Science.
[25] J. Foster,et al. Mining Predicted Essential Genes of Brugia malayi for Nematode Drug Targets , 2007, PloS one.
[26] John P. Overington,et al. Chapter 36. The Molecular Basis of Predicting Druggability , 2008 .
[27] S. Yokoyama,et al. Contribution of structural biology to clinically validated target proteins. , 2008, Drug discovery today.